#Canada #Blainville #Médunik Canada #INCRELEX® #rhIGF-1

Médunik Canada Strengthens Commitment to Rare Diseases

In a monumental development for pediatric healthcare, Médunik Canada has officially become the exclusive distributor of INCRELEX® (mecasermin), a recombinant human insulin-like growth factor-1 (rhIGF-1). This significant partnership aims to improve the support network for children suffering from an ultra-rare growth disorder known as severe primary insulin-like growth factor-1 deficiency (SPIGFD), ensuring they receive the critical treatment they need.

Understanding SPIGFD

SPIGFD is an extremely rare endocrine condition that inhibits the body's production of adequate insulin-like growth factor-1, crucial for normal growth during childhood. Many children affected by this disorder may experience severely stunted growth and face various physical and emotional challenges if appropriate measures are not taken. The introduction of INCRELEX® into the Canadian market is a critical step in ensuring these children have access to effective treatments.

Carla Létourneau, Director of Marketing Strategy at Médunik Canada, expressed her excitement about this new role, stating, “Becoming the exclusive distributor of INCRELEX® in Canada is a natural extension of Médunik Canada's mission to improve the lives of patients with rare conditions.”

The collaboration between Médunik Canada and ESTEVE, a globally recognized pharmaceutical company dedicated to specialized treatments, is aimed at facilitating continuous access to this vital therapy. As part of their ongoing commitment, Médunik will also uphold an existing patient support program, thus guaranteeing that caregivers and patients do not experience disruption in their care.

The Importance of Early Diagnosis

Dr. Cheri Deal, a Pediatric Endocrinologist at CHU Sainte-Justine, emphasized the necessity of early and precise diagnoses for children with SPIGFD, asserting, “Having a therapy like INCRELEX®, combined with comprehensive patient support and education, makes a meaningful difference for children who have limited treatment options.”

Médunik Canada aims to develop a robust infrastructure of care for families navigating the difficult treatment landscape, reiterating their commitment to patient-centered initiatives.

About Médunik Canada

Founded in 2009, Médunik Canada operates under the umbrella of the Duchesnay Pharmaceutical Group and has emerged as a key player in the market for orphan drugs in Canada. Its mission is crystal clear: to enhance the quality of life for Canadians grappling with rare and debilitating diseases. In collaboration with strategic partners, Médunik is focused on research and development aimed at improving healthcare solutions for those in need.

For more detailed information about Médunik's initiatives and available treatments, visit Médunik Canada. Follow their journey on LinkedIn to stay updated on their efforts and projects.

Conclusion

Médunik Canada's exclusive distribution of INCRELEX® stands as a testament to their dedication to addressing the needs of children with SPIGFD. As they continue to expand their support mechanisms, the positive impact of this development is sure to resonate throughout the healthcare community in Canada, fostering hope and assistance for families confronting the challenges posed by rare diseases.